In 2008, the first article to report the expression of IDH mutation in GBM was published by Parsons et al. The authors of the study discovered that IDH1 could be a potential marker for secondary GBM [50], currently known as astrocytoma IDH-mutant CNS WHO grade 4 [10]. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).